VERAXA Biotech (NASDAQ: VRXA) announced on July 2, 2026, the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. The collaboration will apply ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development. This move follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The cell line development is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional 'AND'-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
This news matters because it represents a significant step forward in developing a cancer therapy that may offer better safety and efficacy compared to existing T-cell engagers. Traditional T-cell engagers can cause off-tumor toxicity, limiting their dosing and effectiveness. VERAXA's approach could expand the therapeutic window, potentially benefiting patients with solid tumors that are difficult to treat. The collaboration with ATUM aims to accelerate the path to clinical trials by establishing robust manufacturing processes.
For the biotechnology industry, this development highlights the growing interest in conditional activation technologies to improve the specificity of immunotherapies. If successful, VERAXA's BiTAC platform could set a new standard for T-cell engager design, influencing future drug development. Investors and stakeholders will be watching closely as the company progresses toward IND-enabling studies.
For more information, the full press release is available at https://ibn.fm/FCIlk. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
